ArticleCureus2026
Chemotherapy-Related Adverse Drug Reaction (ADR) Profile in Geriatric Cancer Patients: A Prospective Study From Western India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Chemotherapy adverse drug reactions (ADRs) among geriatric cancer patients (≥65 years) are a major cause of morbidity. Real-world data for the Western Indian population are lacking. In the absence of data and guidelines, geriatric patients either suffer treatment-related toxicities or remain undertreated. The present study aimed to study the clinical profile, geriatric assessment (GA), chemotherapy-related ADRs, and survival outcomes. Methods This prospective, observational study enrolled patients aged ≥65 years who were starting curative-intent chemotherapy. Baseline clinical and GA was performed. Treatment details, including planned chemotherapy regimens and modifications in chemotherapy dosing, schedule, or protocol selection based on initial assessments, were recorded. Chemotherapy-related ADRs were assessed using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). Grade 3-5 adverse events were defined as severe. In total, 150 patients were accrued. Patients were followed up for one year post-chemotherapy. Results Out of 150 patients, 72 patients (48%) completed all planned cycles. Forty-nine patients (32.66%) reported severe-grade ADRs (CTCAE grades 3, 4, and 5). A total of nine (6%) deaths were reported during chemotherapy (i.e., CTCAE grade 5). The baseline GA parameters were not associated with CTCAE grade (p value > 0.05, nonsignificant). The estimated Kaplan-Meier survival at the end of four years of follow-up suggests worse outcomes in patients who experienced severe-grade ADRs and were unable to complete all the planned chemotherapy cycles. Conclusions A significant proportion of geriatric cancer patients experience severe-grade chemotherapy ADRs. Completing planned chemotherapy cycles in patients being treated with curative intent is an important determinant of survival. Patients who experience severe-grade toxicities have adverse survival outcomes, emphasizing the need for personalized toxicity management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.